Blurbs

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Insmed (INSMResearch Report), Regulus (RGLSResearch Report) and Heron Therapeutics (HRTXResearch Report) with bullish sentiments.

Insmed (INSM)

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Insmed, with a price target of $55.00. The company’s shares closed last Monday at $22.30, close to its 52-week low of $21.09.

According to TipRanks.com, Bayko is a 4-star analyst with an average return of 7.7% and a 41.7% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Kiniksa Pharmaceuticals.

Insmed has an analyst consensus of Strong Buy, with a price target consensus of $50.00.

See Insiders’ Hot Stocks on TipRanks >>

Regulus (RGLS)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Regulus today and set a price target of $2.00. The company’s shares closed last Monday at $0.20, close to its 52-week low of $0.19.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -33.3% and a 14.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Aquestive Therapeutics, and Oncternal Therapeutics.

Currently, the analyst consensus on Regulus is a Moderate Buy with an average price target of $1.21.

Heron Therapeutics (HRTX)

Evercore ISI analyst Joshua Schimmer maintained a Buy rating on Heron Therapeutics yesterday and set a price target of $60.00. The company’s shares closed last Monday at $8.53, close to its 52-week low of $7.85.

According to TipRanks.com, Schimmer is a 4-star analyst with an average return of 8.9% and a 48.5% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, BioMarin Pharmaceutical, and Rocket Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Heron Therapeutics with a $35.67 average price target, implying a 337.7% upside from current levels. In a report issued on January 18, Jefferies also assigned a Buy rating to the stock with a $23.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on INSM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos